Bluebird’s gene therapy for beta-thalassemia falls short of a cure, but still wows in 22 patients

After going back to the drawing board to come up with a better gene therapy for beta-thalassemia, a disease that interferes with the body’s ability to produce hemoglobin, investigators working for bluebird bio $BLUE have produced some compelling data to demonstrate that their therapy can eliminate or reduce the need for blood transfusions.